Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
about
Myelin-specific multiple sclerosis antibodies cause complement-dependent oligodendrocyte loss and demyelination.The Multiple Sclerosis (MS) Genetic Risk Factors Indicate both Acquired and Innate Immune Cell Subsets Contribute to MS Pathogenesis and Identify Novel Therapeutic Opportunities.The innovative development in interferon beta treatments of relapsing-remitting multiple sclerosis.Melanoma complicating treatment with natalizumab for multiple sclerosis: A report from the Southern Network on Adverse Reactions (SONAR)Effect of Fingolimod on Brain Volume Loss in Patients with Multiple Sclerosis.MicroRNAs: Roles in Regulating Neuroinflammation.An update on cladribine for relapsing-remitting multiple sclerosis.Daclizumab for the treatment of multiple sclerosis.An update on multiple sclerosis in children: diagnosis, therapies, and prospects for the future.Differential effects of FTY720 on the B cell compartment in a mouse model of multiple sclerosis.Ocrelizumab: a B-cell depleting therapy for multiple sclerosis.Therapeutic Targets for Multiple Sclerosis: Current Treatment Goals and Future Directions.Cost-effectiveness analysis of ocrelizumab versus subcutaneous interferon beta-1a for the treatment of relapsing multiple sclerosis.The Role of Peripheral CNS-Directed Antibodies in Promoting Inflammatory CNS Demyelination.Health-Related Quality of Life in Patients with Multiple Sclerosis: Impact of Disease-Modifying Drugs.Biotherapy in Inflammatory Diseases of the CNS: Current Knowledge and Applications.Daclizumab for the treatment of relapsing-remitting multiple sclerosis.Adaptive Immunity Is the Key to the Understanding of Autoimmune and Paraneoplastic Inflammatory Central Nervous System Disorders.Modulating inflammation and neuroprotection in multiple sclerosis.Ocrelizumab and Other CD20(+) B-Cell-Depleting Therapies in Multiple Sclerosis.Daclizumab: Development, Clinical Trials, and Practical Aspects of Use in Multiple Sclerosis.Efficiency of antibody therapy in demyelinating diseases.Cerebrospinal fluid B cells and disease progression in multiple sclerosis - A longitudinal prospective study.Monoclonal Antibodies in Preclinical EAE Models of Multiple Sclerosis: A Systematic Review.JC Polyomavirus Attachment and Entry: Potential Sites for PML Therapeutics.It's Time For Combination Therapies: in Multiple SclerosisIn Silico Prediction Analysis of Idiotope-Driven T-B Cell Collaboration in Multiple Sclerosis.B-cell-targeted therapies in relapsing forms of MS.Imaging outcome measures for progressive multiple sclerosis trialsUnderstanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program.The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations.The Genetics of Multiple Sclerosis: From 0 to 200 in 50 Years.The Role of the Gut Microbiome in Multiple Sclerosis Risk and Progression: Towards Characterization of the "MS Microbiome".B Cell Therapy for Multiple Sclerosis: Entering an Era.Regulation and dysregulation of axon infrastructure by myelinating glia.Remyelinating Pharmacotherapies in Multiple Sclerosis.Deciphering the Role of B Cells in Multiple Sclerosis-Towards Specific Targeting of Pathogenic Function.The chronically inflamed central nervous system provides niches for long-lived plasma cells.Novel pathomechanisms in inflammatory neuropathies.Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis.
P2860
Q30842875-6BDBA239-64C7-4266-BD81-2D72B0C9D9EAQ33572483-2E897CD0-57F7-4FA4-93D6-9B073477213FQ33810082-3C0B03C3-8A6D-49B0-A5FD-0E9AB0CA759EQ33891255-C8438965-4AE3-4AED-B26E-E704D1B8C1CAQ36293431-7A7881AB-0496-4416-A405-DD9C1D998E93Q38287691-46486196-A1FB-481C-BB15-6042A48CF875Q38600051-F3BED759-F24B-4B23-A4BD-5702B5533B38Q38604207-5DCC046C-60AA-4FFE-9637-81F434FF7AD9Q38652593-D0FB4DEE-B30E-46BF-A5C0-E4EE82B6A828Q38664253-7D6DF8E7-CECB-4922-9CB6-764C71921FA7Q38665518-C8AB2CEC-8988-4871-990C-A328F4183E60Q38666303-0280D557-E6D8-4187-B587-3870BFC42832Q38681227-5C1BCC98-2EEF-4625-B073-FB65B6F30DCFQ38714054-8A721794-5C1C-4AD1-91DA-C0D7144E19F4Q38728373-C743C357-0DC0-4607-AF35-B23E0E60A479Q38729214-B6F05FC4-B4F0-4738-82BA-376E0BC6F44CQ39175716-C4C6D505-6F6B-4FC6-8771-1E48150717F5Q39225440-DE8DC620-0FCA-48BD-89ED-BB0273EF30D6Q39350409-B43324A7-8AD6-4BA8-9223-276949488C3EQ39427711-8036E737-89B2-420D-8853-3A7F093156F8Q39434495-BAE4DB6D-5C1C-438C-AA59-F16223F7BC27Q40045794-DC5DDF8D-1003-4736-95A9-D665E836F3EAQ41255081-23716DFE-87A6-43B3-9899-99D73EA7810FQ41660408-EC1C1871-E4EF-4A9F-A5A1-D33C385E21D6Q41921811-AC0A17A1-6A46-4FEB-BF72-A180728F2F1CQ42360915-72F2B1B6-CC63-47C9-9BF8-AC9953F9FE02Q42371905-236371CC-CB73-4BDB-9312-5D39A5761680Q42631407-E82A8617-98EB-40B8-BCAA-149BE7A94E1FQ42660399-55845622-3B5E-4143-A648-4E59F85A14C4Q44757011-8B98A005-55AB-4EB5-BE68-4A95D381828FQ45066717-1F569455-972A-4ABB-9516-5722ABAEAFB4Q45949302-24DD6922-8040-4E77-84CE-92803EFB6260Q46181413-1372A540-5B5E-44A2-B474-B2E9C38C15E7Q46583404-AC8E654F-E8A2-4346-A96C-5F02D3E337DFQ46614637-779BE126-80C5-4A5C-A2F0-B4F4B2F211A3Q46682011-6EAE0DC6-F13A-42D1-9797-86F53790BF44Q47102132-4398FE75-0184-4140-A5BE-7D3A984DE366Q47116115-71254CF4-13C9-4759-A974-487194389408Q47126672-B26BD054-4D57-4325-AA46-3EEE7C6D38E4Q47198260-E4D2112A-12B6-4A33-99A4-2CE1247A240A
P2860
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
@en
type
label
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
@en
prefLabel
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
@en
P2093
P50
P356
P1476
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
@en
P2093
Amit Bar-Or
Anthony Traboulsee
Bernhard Hemmer
Donna Masterman
Douglas L Arnold
Fred Lublin
Gaelle Klingelschmitt
Hideki Garren
Jerry S Wolinsky
Kottil W Rammohan
P304
P356
10.1056/NEJMOA1601277
P407
P577
2016-12-21T00:00:00Z